DK2139483T3 - Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer - Google Patents

Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer

Info

Publication number
DK2139483T3
DK2139483T3 DK08742674.8T DK08742674T DK2139483T3 DK 2139483 T3 DK2139483 T3 DK 2139483T3 DK 08742674 T DK08742674 T DK 08742674T DK 2139483 T3 DK2139483 T3 DK 2139483T3
Authority
DK
Denmark
Prior art keywords
pi3k
quinoxaline
cancer
inhibitor
alpha
Prior art date
Application number
DK08742674.8T
Other languages
Danish (da)
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of DK2139483T3 publication Critical patent/DK2139483T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08742674.8T 2007-04-11 2008-04-08 Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer DK2139483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK2139483T3 true DK2139483T3 (da) 2014-01-13

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08742674.8T DK2139483T3 (da) 2007-04-11 2008-04-08 Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer

Country Status (33)

Country Link
US (1) US8481001B2 (OSRAM)
EP (1) EP2139483B9 (OSRAM)
JP (2) JP5726515B2 (OSRAM)
KR (1) KR101586774B1 (OSRAM)
CN (2) CN103202842A (OSRAM)
AU (1) AU2008239668B2 (OSRAM)
BR (1) BRPI0810208A2 (OSRAM)
CA (1) CA2684056A1 (OSRAM)
CO (1) CO6140024A2 (OSRAM)
CR (1) CR11099A (OSRAM)
CY (1) CY1114608T1 (OSRAM)
DK (1) DK2139483T3 (OSRAM)
EA (1) EA019064B1 (OSRAM)
EC (1) ECSP099723A (OSRAM)
ES (1) ES2438998T3 (OSRAM)
GT (1) GT200900263A (OSRAM)
HR (1) HRP20131081T1 (OSRAM)
IL (1) IL201211A (OSRAM)
MA (1) MA31335B1 (OSRAM)
ME (1) ME00937B (OSRAM)
MX (1) MX2009010929A (OSRAM)
MY (1) MY150797A (OSRAM)
NI (1) NI200900184A (OSRAM)
NZ (1) NZ580009A (OSRAM)
PL (1) PL2139483T3 (OSRAM)
PT (1) PT2139483E (OSRAM)
RS (1) RS53020B (OSRAM)
SI (1) SI2139483T1 (OSRAM)
SV (1) SV2009003390A (OSRAM)
TN (1) TN2009000399A1 (OSRAM)
UA (1) UA98141C2 (OSRAM)
WO (1) WO2008127594A2 (OSRAM)
ZA (1) ZA200906765B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608667A (en) * 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
DK2139484T3 (da) * 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
EP2374802B1 (en) 2008-11-10 2014-04-23 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US9011863B2 (en) 2010-07-09 2015-04-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
EA201390582A1 (ru) 2010-10-20 2013-09-30 Мерк Сероно С.А. Женева Способ получения замещенных n-(3-аминохиноксалин-2-ил)сульфонамидов и их промежуточных n-(3-хлорхиноксалин-2-ил)сульфонамидов
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
TW201325592A (zh) * 2011-09-14 2013-07-01 Exelixis Inc 用於治療癌症之磷脂醯肌醇－３激酶抑制劑
WO2013052699A2 (en) * 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
JP2014532647A (ja) * 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
KR20140096083A (ko) * 2011-11-01 2014-08-04 엑셀리시스, 인코포레이티드 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ­（3­｛［（3­｛［2­클로로­5­（메톡시）페닐］아미노｝퀴녹살린­2­일）아미노］설포닐｝페닐）­2­메틸알라닌아미드
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
US20150010545A1 (en) * 2011-12-27 2015-01-08 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
WO2015055071A1 (zh) 2013-10-16 2015-04-23 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276527A1 (en) * 2003-01-17 2006-12-07 Thresold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US8071597B2 (en) * 2005-08-26 2011-12-06 Merck Serono Sa Pyrazine compounds and uses as PI3K inhibitors
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
NZ608667A (en) * 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ZA200904857B (en) 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
DK2139484T3 (da) * 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
EA019064B1 (ru) 2013-12-30
JP2014074031A (ja) 2014-04-24
CR11099A (es) 2010-01-19
EP2139483B1 (en) 2013-09-18
CO6140024A2 (es) 2010-03-19
JP5726515B2 (ja) 2015-06-03
GT200900263A (es) 2014-01-15
HRP20131081T1 (hr) 2013-12-20
EA200970935A1 (ru) 2010-04-30
KR20100019436A (ko) 2010-02-18
ECSP099723A (es) 2010-03-31
SV2009003390A (es) 2010-05-21
ES2438998T3 (es) 2014-01-21
IL201211A (en) 2015-09-24
BRPI0810208A2 (pt) 2014-10-21
CN101959516A (zh) 2011-01-26
US20110123434A1 (en) 2011-05-26
KR101586774B1 (ko) 2016-01-19
RS53020B (sr) 2014-04-30
CN101959516B (zh) 2013-05-08
AU2008239668B2 (en) 2013-11-07
AU2008239668A1 (en) 2008-10-23
ME00937B (me) 2012-06-20
EP2139483B9 (en) 2014-05-21
WO2008127594A3 (en) 2009-04-30
MA31335B1 (fr) 2010-04-01
US8481001B2 (en) 2013-07-09
ZA200906765B (en) 2010-05-26
MX2009010929A (es) 2010-01-20
CN103202842A (zh) 2013-07-17
NI200900184A (es) 2011-09-08
NZ580009A (en) 2012-06-29
UA98141C2 (ru) 2012-04-25
HK1140141A1 (en) 2010-10-08
SI2139483T1 (sl) 2013-11-29
JP2010523669A (ja) 2010-07-15
MY150797A (en) 2014-02-28
CA2684056A1 (en) 2008-10-23
PT2139483E (pt) 2013-12-27
CY1114608T1 (el) 2016-10-05
IL201211A0 (en) 2010-05-31
PL2139483T3 (pl) 2014-02-28
TN2009000399A1 (fr) 2010-12-31
EP2139483A2 (en) 2010-01-06
WO2008127594A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
DK2205257T3 (da) Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
CL2007002783S1 (es) Inhalador multidosis.
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2233135T3 (da) Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
EP2142239A4 (en) INHALATION DEVICE
BRPI0813235A2 (pt) Combinação anti-helmíntica.
EP2195010A4 (en) TREATMENT WITH INHIBITORS OF KALLIKREINE
EP2131904A4 (en) Dose counter
DK2144905T3 (da) Terapeutiske midler
BRPI0814736A2 (pt) inalador.
BRPI0813670A2 (pt) Compostos para tratamento
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2173831T3 (da) Brøndbehandling
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
DK2033675T3 (da) Inhalationsapparat
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802